Investment will help fuel international partnerships, scale production of its early autism diagnostic aid test – StrandDx™ASD – which is expected to become available to the public in 2024 North Brunswick, NJ – May 31, 2023 – LinusBio, a leader in precision exposome sequencing, and Y.A.C. Holdings, a Japanese multinational, today announced a partnership with a …
The company set to unveil an early autism and ALS detection and treatment platform New York City – January 13, 2023 – LinusBio, a leader in precision exposome sequencing, today announced it raised over $16 million in Series A funding to deliver a novel platform that bridges genomics, the environment, and biological response. Historically, many health …
LinusBio Raises $16 Million to Scale Growth and Deliver Tangible Outcomes Read More »
Novozymes, the world leader in biological solutions, and LinusBio (Linus Biotechnology Inc.), a leader in precision exposome sequencing, today announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial. The project will apply LinusBio’s environmental biodynamics platform, enabling detailed temporal mapping of harmful compound exposure, to a clinical …
Dr. Manish Arora Speaks at the Innovation Awards ceremony. Photo by Monika Graff Contact: mg@monikagraff.com The Biotech Startup, That Developed A Novel Precision Exposome Sequencing Platform, Has Been Selected As The Winner Of The Transaction Of The Year Award On Monday October 24 2022, the Icahn School of Medicine at Mount Sinai hosted the 8th annual Mount …
LinusBio Recognized at the 2022 Mount Sinai Innovation Awards Read More »
Watch the webinar: Manish Arora, PhD, Founder, CEO and CSO at Linus Bio, speaks at the Institute for Exposomic Research at Mount Sinai.
Manish Arora, PHD, Co-Founder of Linus Biotechnology speaks at HITLAB 2021 Innovator’s Summit Presentation.
NEW YORK, Dec. 7, 2021 /PRNewswire/ — Linus Biotechnology Inc., a leader in precision exposome sequencing, today announced that the U.S. Food and Drug Administration Center for Devices and Radiological Health has granted the Company’s StrandDx™-ASD diagnostic aid the designation as a Breakthrough Device for Autism Spectrum Disorder (ASD). The FDA Breakthrough Device designation aims to expedite …
NEW YORK, Nov. 17, 2021 /PRNewswire/ — Linus Biotechnology Inc. (“LinusBio” or the “Company”) and Mount Sinai Innovation Partners (MSIP) today announced an exclusive worldwide license and collaboration agreement in progress with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai), the medical school of the Mount Sinai Health System (Mount Sinai). LinusBio is a novel biotechnology company …
